[go: up one dir, main page]

IN2014DN10214A - - Google Patents

Info

Publication number
IN2014DN10214A
IN2014DN10214A IN10214DEN2014A IN2014DN10214A IN 2014DN10214 A IN2014DN10214 A IN 2014DN10214A IN 10214DEN2014 A IN10214DEN2014 A IN 10214DEN2014A IN 2014DN10214 A IN2014DN10214 A IN 2014DN10214A
Authority
IN
India
Prior art keywords
disorders
allergies
crohn
modulate
contemplated
Prior art date
Application number
Inventor
Daan Hommes
Auke Verhaar
Brink Gijs Van Den
Francesca Viti
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Publication of IN2014DN10214A publication Critical patent/IN2014DN10214A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure is directed in part to bicyclic heterocycles such as a compound represented by formula (I) or (II) as disclosed herein and their use in treating medical disorders such as immune inflammatory disorders such as Crohn s disease ulcerative colitis rheumatic disorders psoriasis and allergies. The compounds are contemplated to modulate T Cell responses.
IN10214DEN2014 2012-06-01 2013-05-31 IN2014DN10214A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261654398P 2012-06-01 2012-06-01
PCT/EP2013/061328 WO2013178815A1 (en) 2012-06-01 2013-05-31 Bicyclic heterocycles capable of modulating t-cell responses, and methods of using same

Publications (1)

Publication Number Publication Date
IN2014DN10214A true IN2014DN10214A (en) 2015-08-07

Family

ID=48538005

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10214DEN2014 IN2014DN10214A (en) 2012-06-01 2013-05-31

Country Status (11)

Country Link
US (2) US20150126553A1 (en)
EP (1) EP2861563B1 (en)
JP (1) JP2015521195A (en)
KR (1) KR20150016377A (en)
CN (1) CN104619687A (en)
AU (1) AU2013269550A1 (en)
BR (1) BR112014030039A2 (en)
CA (1) CA2874919A1 (en)
IN (1) IN2014DN10214A (en)
MX (1) MX2014014657A (en)
WO (1) WO2013178815A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20050389A1 (en) 2005-07-22 2007-01-23 Giuliani Spa COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS.
UA107562C2 (en) 2008-12-05 2015-01-26 METHOD OF TREATMENT OF PSORIASIS
BRPI1011226B1 (en) 2009-02-16 2019-10-29 Giuliani Internacional Ltd use of a pharmaceutical composition to treat hair related conditions
CN109999017A (en) 2012-02-09 2019-07-12 诺格拉制药有限公司 The method for treating fibrosis
CA2870490A1 (en) 2012-04-18 2013-10-24 Nogra Pharma Limited Methods of treating lactose intolerance
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
US20190016680A1 (en) 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
CN112165940A (en) * 2018-03-27 2021-01-01 德克萨斯州立大学董事会 OX2R compounds
DK3921299T3 (en) 2019-02-08 2025-01-27 Nogra Pharma Ltd PROCESS FOR THE PRODUCTION OF 3-(4'-AMINOPHENYL)-2-METHOXYPROPIONIC ACID AND ITS ANALOGUES AND INTERMEDIATES
IL297781A (en) 2020-05-06 2022-12-01 Merck Sharp & Dohme Llc Il4i1 inhibitors and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1069385A1 (en) * 1982-05-07 1990-11-15 Научно-исследовательский институт фармакологии АМН СССР Bromide of 2-amino-(1-adamantylcarbonylmethyl)-1-(beta-piperidinoethyl)-benzimidazolium displaying immuno-suppression activity
US7868028B2 (en) * 2002-06-17 2011-01-11 Fred Drasner Guanidine compounds as anesthetics and for treatment of nervous system disorders
DE602006019213D1 (en) * 2005-03-15 2011-02-10 Pfizer BENZIMIDAZOLON DERIVATIVES AS CB2 RECEPTOR LIGANDS
AU2006283592A1 (en) * 2005-08-22 2007-03-01 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
EP1983992A4 (en) * 2006-01-19 2010-08-18 Abbott Lab 2-imino-benzimidazoles
US20080206287A1 (en) * 2006-09-18 2008-08-28 Reed John C Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands
EA018976B1 (en) * 2008-03-07 2013-12-30 Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А. 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND p40
CA2715065C (en) * 2008-03-07 2017-06-27 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression mcp-1 and cx3cr1

Also Published As

Publication number Publication date
CA2874919A1 (en) 2013-12-05
US20170183313A1 (en) 2017-06-29
CN104619687A (en) 2015-05-13
AU2013269550A1 (en) 2014-12-18
EP2861563A1 (en) 2015-04-22
BR112014030039A2 (en) 2017-06-27
WO2013178815A1 (en) 2013-12-05
KR20150016377A (en) 2015-02-11
JP2015521195A (en) 2015-07-27
EP2861563B1 (en) 2017-07-12
MX2014014657A (en) 2015-08-10
US20150126553A1 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
IN2014DN10214A (en)
MX366205B (en) Heterocycles capable of modulating t-cell responses, and methods of using same.
CY1122266T1 (en) 3-AMINOCYCLALKYL COMPOUNDS AS ROR-GAMMA-T INHIBITORS AND USES THEREOF
PH12016500225A1 (en) Novel quinoline-substituted compound
JO3131B1 (en) Chemical compounds
PH12016502167A1 (en) Hdl theraphy markers
MX364486B (en) Pyridazinone-amides derivatives.
NZ626618A (en) Hydroxamic acid derivatives and uses thereof
IN2015DN01156A (en)
SI2880447T1 (en) Markers associated with sensitivity to inhibitors of human double minute 2 (mdm2)
PH12015502161A1 (en) Therapeutic compounds and compositions
UA116648C2 (en) FUMARATS AS A PRODUCT AND THEIR USE IN THE TREATMENT OF DIFFERENT DISEASES
MX380943B (en) THERAPEUTIC ACTIVE COMPOUNDS AND THEIR METHODS OF USE.
MX2015011273A (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3kî´ related disorders.
NZ727304A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
AR093457A1 (en) BENDAMUSTINE DERIVATIVES AND METHODS TO USE THEM
MX2016006975A (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases.
MX2016005760A (en) Gsk-3 inhibitors.
NZ700283A (en) Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
MX2020005533A (en) Novel process for making compounds for use in the treatment of cancer.
NZ707773A (en) Methods of treating liver diseases
UY33973A (en) METHODS OF DIRECTED TREATMENT OF FRONTOTEMPORARY LOBULAR DEGENERATION.
MX2020006075A (en) Bendamustine pharmaceutical compositions.
IN2014KN01772A (en)
MX2015005312A (en) 1 h-indole-3-carboxamide derivatives and use thereof as p2y12 antagonists.